Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jacklyn Nemunaitis"'
Publikováno v:
Cancer Research. 81:PS14-20
Human epidermal growth factor receptor 2 (HER2) positive (+) breast cancer is a disease with distinct clinicopathological features. Survival for women with HER2+ disease has increased with the development of novel systemic therapeutic agents, however
Autor:
Sangeetha Prabhakaran, V. Shane Pankratz, Christopher McNicoll, Nadja Falk, Jacklyn Nemunaitis, Jain Zhou, Payton Sandoval-Belt
Publikováno v:
Cancer Research. 83:P6-01
Background: Response to neoadjuvant chemotherapy (NAC) is an indicator of outcomes and can be quantified as achievement of pathologic complete response (pCR) (absence of residual invasive disease in breast and lymph nodes) and residual percent cellul
Autor:
Zoneddy Dayao, Jacklyn Nemunaitis
Publikováno v:
Cancer Research. 79:P5-13
Background: NCI-designated centers struggle to meet the 10% minimum accrual benchmark even for common malignancies such as breast cancer. The University of New Mexico Comprehensive Cancer Center (UNMCCC) average annual breast cancer trial accrual rat
Autor:
Sangeetha Prabhakaran, Christopher McNicoll, Vernon S. Pankratz, Nadja Falk, Jacklyn Nemunaitis, Jain Zhou, Payton A. Sandoval-Belt
Publikováno v:
Cancer Research. 82:3686-3686
Background: Response to neoadjuvant chemotherapy (NAC) for breast cancer varies by tumor characteristics and therapy regimen. Studies suggest that patient ethnicity is associated with differences in disease presentation, response to treatment, and ou
Autor:
Harsh Sharma, Jordyn Kreutzfeldt, Tej Mehta, Kiah Farr, Ursa Brown-Glaberman, Pavani Chalasani, Jacklyn Nemunaitis, Jennifer Margaret Segar
Publikováno v:
Journal of Clinical Oncology. 40:e12630-e12630
e12630 Background: In HER2+ early breast cancer, dual HER2 targeted combination of trastuzumab and pertuzumab with chemotherapy achieved higher rates of pathologic complete response (pCR) and improved long term outcomes. However, the optimal chemothe
Autor:
Ursa Brown-Glabeman, Itzhak Nir, Jacklyn Nemunaitis, Victor H Phuoc, Ben Liem, Rama R. Gullapalli, Jessica Belmonte, Heloisa P. Soares
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-14 (2018)
BMC Cancer
BMC Cancer
Gallbladder cancer is a rare malignancy of the biliary tract with a poor prognosis, frequently presenting at an advanced stage. While rare in the United States overall, gallbladder cancer has an elevated incidence in geographically distinct locations
Autor:
Jacklyn Nemunaitis, Cecilia Arana-Yi, Shazib Sagheer, Morgan Wong, Arpit Rao, David R. Czuchlewski
Publikováno v:
Clinical Case Reports
Key Clinical Message Hemophagocytosis Lymphocytosis (HLH) is a rare and life‐threatening illness that is more commonly seen in infants; however, its incidence in adults is becoming more common. Recognizing HLH in a complicated clinical scenario is
Autor:
Sangeetha Prabhakaran, Nadja Falk, Kaitlyn J Nielson, Jacklyn Jacklyn Nemunaitis, Edgar G. Fischer
Publikováno v:
Case Reports in Clinical Pathology. 7:46
Breast tall cell carcinoma with reversed polarity (TCCRP) is rare and previously referred to as solid papillary carcinoma with reverse polarity. This low grade tumor commonly exhibits IDH2 p.Arg172 mutation, however is not completely understood at th
Autor:
Cristhiam M. Rojas-Hernandez, Kristopher D. Marjon, Jennifer M. Gillette, Daniel Bustamante, Jacklyn Nemunaitis, Qian Yun Zhang
Publikováno v:
BMC Hematology
Background Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The frequency of symptomatic central nervous system (CNS) involvement is unknown but thought to be a rare phenomenon. Currently there are no known risk fa
Autor:
Neil Senzer, Joseph A. Kuhn, Peter D. Beitsch, Anton Melnyk, Phillip B. Maples, Gladice Wallraven, Jonathan Oh, John Nemunaitis, Minal A. Barve, Beena O. Pappen, Donald Rao, Mitchell Magee, Cynthia Bedell, Padmasini Kumar, Jacklyn Nemunaitis, Charles Brunicardi F
Publikováno v:
Journal of Vaccines & Vaccination.
Study Background: Previously, we demonstrated safety and correlated induced immune response with survival in a Phase I study of FANG immunotherapy in advanced cancer patients. We now report long term follow-up (FU) of Phase I treated patients includi